NAPDH oxidase mediates glucolipotoxicity-induced beta cell dysfunction - Clinical implications

Medical Hypotheses

Volumn 74, Issue 3, 2010, Pages 596-600

  McCarty, Mark F ^a   Barroso Aranda, Jorge ^a   Contreras, Francisco ^a  

^a Oasis of Hope Hospital   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; APOCYNIN; BILIRUBIN; BILIVERDIN; BIOTIN; CARBOHYDRATE; CELL PROTEIN; CYCLIC AMP; ENZYME INHIBITOR; EXENDIN 4; FATTY ACID; GLUCOKINASE; GLUCOSE; INCRETIN; PHYCOCYANIN; PHYCOCYANOBILIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR PDX 1; UNCLASSIFIED DRUG; INSULIN;

APOPTOSIS; ARTICLE; CARBOHYDRATE ABSORPTION; CELL DEATH; CELL DIFFERENTIATION; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETOGENESIS; DIET THERAPY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SCREENING; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME INHIBITOR COMPLEX; GILBERT DISEASE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET CELL FUNCTION; PANCREAS ISLET DISEASE; PROTEIN EXPRESSION; RISK FACTOR; SPIRULINA; ANIMAL; BIOLOGICAL MODEL; METABOLISM; PANCREAS ISLET BETA CELL; SECRETION;

SPIRULINA;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MODELS, BIOLOGICAL; NADPH OXIDASE; OXIDATIVE STRESS;

EID: 77649274275     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.09.062     Document Type: Article

References (83)

1. Del G.S., Lupi R., Marselli L., Masini M., Bugliani M., Sbrana S., et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes 2005, 54(3):727-735.
2. Marchetti P., Del P.S., Lupi R., Del G.S. The pancreatic beta-cell in human Type 2 diabetes. Nutr Metab Cardiovasc Dis 2006, 16(Suppl 1):S3-S6.
3. Sakuraba H., Mizukami H., Yagihashi N., Wada R., Hanyu C., Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 2002, 45(1):85-96.
4. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52(1):102-110.
5. Matschinsky F.M. Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes. Diabetes 1990, 39(6):647-652.
6. Efrat S., Tal M., Lodish H.F. The pancreatic beta-cell glucose sensor. Trends Biochem Sci 1994, 19(12):535-538.
7. Robertson R.P. Type II diabetes, glucose "non-sense" , and islet desensitization. Diabetes 1989, 38(12):1501-1505.
8. Zangen D.H., Bonner-Weir S., Lee C.H., Latimer J.B., Miller C.P., Habener J.F., et al. Reduced insulin, GLUT2, and IDX-1 in beta-cells after partial pancreatectomy. Diabetes 1997, 46(2):258-264.
9. Lee Y., Hirose H., Ohneda M., Johnson J.H., McGarry J.D., Unger R.H. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci USA 1994, 91(23):10878-10882.
10. Mason T.M., Goh T., Tchipashvili V., Sandhu H., Gupta N., Lewis G.F., et al. Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats. Diabetes 1999, 48(3):524-530.
11. Gremlich S., Bonny C., Waeber G., Thorens B. Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and somatostatin levels. J Biol Chem 1997, 272(48):30261-30269.
12. Leahy J.L., Cooper H.E., Deal D.A., Weir G.C. Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. A study in normal rats using chronic in vivo glucose infusions. J Clin Invest 1986, 77(3):908-915.
13. Dubois M., Kerr-Conte J., Gmyr V., Bouckenooghe T., Muharram G., D'Herbomez M., et al. Non-esterified fatty acids are deleterious for human pancreatic islet function at physiological glucose concentration. Diabetologia 2004, 47(3):463-469.
14. Poitout V., Robertson R.P. Minireview: secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002, 143(2):339-342.
15. Watada H., Kajimoto Y., Umayahara Y., Matsuoka T., Kaneto H., Fujitani Y., et al. The human glucokinase gene beta-cell-type promoter: an essential role of insulin promoter factor 1/PDX-1 in its activation in HIT-T15 cells. Diabetes 1996, 45(11):1478-1488.
16. Kaneto H., Miyatsuka T., Shiraiwa T., Yamamoto K., Kato K., Fujitani Y., et al. Crucial role of PDX-1 in pancreas development, beta-cell differentiation, and induction of surrogate beta-cells. Curr Med Chem 2007, 14(16):1745-1752.
17. El-Assaad W., Buteau J., Peyot M.L., Nolan C., Roduit R., Hardy S., et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 2003, 144(9):4154-4163.
18. McCarty M.F. Incorporation of beta cell redifferentiation therapy into a lipoprivic strategy for reversing type 2 diabetes. Med Hypotheses 2002, 58(6):462-471.
19. Wing R.R., Marcus M.D., Salata R., Epstein L.H., Miaskiewicz S., Blair E.H. Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects. Arch Intern Med 1991, 151(7):1334-1340.
20. Henry R.R., Gumbiner B. Benefits and limitations of very-low-calorie diet therapy in obese NIDDM. Diabetes Care 1991, 14(9):802-823.
21. Wing R.R., Blair E.H., Bononi P., Marcus M.D., Watanabe R., Bergman R.N. Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 1994, 17(1):30-36.
22. Rubino F., Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 2002, 236(5):554-559.
23. Polyzogopoulou E.V., Kalfarentzos F., Vagenakis A.G., Alexandrides T.K. Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes 2003, 52(5):1098-1103.
24. Kaneto H., Xu G., Fujii N., Kim S., Bonner-Weir S., Weir G.C. Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. J Biol Chem 2002, 277(33):30010-30018.
25. Kawamori D., Kajimoto Y., Kaneto H., Umayahara Y., Fujitani Y., Miyatsuka T., et al. Oxidative stress induces nucleo-cytoplasmic translocation of pancreatic transcription factor PDX-1 through activation of c-Jun NH(2)-terminal kinase. Diabetes 2003, 52(12):2896-2904.
26. Kaneto H., Kawamori D., Matsuoka T.A., Kajimoto Y., Yamasaki Y. Oxidative stress and pancreatic beta-cell dysfunction. Am J Ther 2005, 12(6):529-533.
27. Kaneto H., Kajimoto Y., Miyagawa J., Matsuoka T., Fujitani Y., Umayahara Y., et al. Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity. Diabetes 1999, 48(12):2398-2406.
28. Gorogawa S., Kajimoto Y., Umayahara Y., Kaneto H., Watada H., Kuroda A., et al. Probucol preserves pancreatic beta-cell function through reduction of oxidative stress in type 2 diabetes. Diabetes Res Clin Pract 2002, 57(1):1-10.
29. Kawamori D., Kaneto H., Nakatani Y., Matsuoka T.A., Matsuhisa M., Hori M., et al. The forkhead transcription factor Foxo1 bridges the JNK pathway and the transcription factor PDX-1 through its intracellular translocation. J Biol Chem 2006, 281(2):1091-1098.
30. Marshak S., Benshushan E., Shoshkes M., Havin L., Cerasi E., Melloul D. Functional conservation of regulatory elements in the pdx-1 gene: PDX-1 and hepatocyte nuclear factor 3beta transcription factors mediate beta-cell-specific expression. Mol Cell Biol 2000, 20(20):7583-7590.
31. Olson L.K., Sharma A., Peshavaria M., Wright C.V., Towle H.C., Rodertson R.P., et al. Reduction of insulin gene transcription in HIT-T15 beta cells chronically exposed to a supraphysiologic glucose concentration is associated with loss of STF-1 transcription factor expression. Proc Natl Acad Sci USA 1995, 92(20):9127-9131.
32. Macfarlane W.M., McKinnon C.M., Felton-Edkins Z.A., Cragg H., James R.F., Docherty K. Glucose stimulates translocation of the homeodomain transcription factor PDX1 from the cytoplasm to the nucleus in pancreatic beta-cells. J Biol Chem 1999, 274(2):1011-1016.
33. Elrick L.J., Docherty K. Phosphorylation-dependent nucleocytoplasmic shuttling of pancreatic duodenal homeobox-1. Diabetes 2001, 50(10):2244-2252.
34. Hagren O.I., Tengholm A. Glucose and insulin synergistically activate phosphatidylinositol 3-kinase to trigger oscillations of phosphatidylinositol 3, 4, 5-trisphosphate in beta-cells. J Biol Chem 2006, 281(51):39121-39127.
35. Aguirre V., Uchida T., Yenush L., Davis R., White M.F. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000, 275(12):9047-9054.
36. Andreozzi F., D'Alessandris C., Federici M., Laratta E., Del G.S., Del P.S., et al. Activation of the hexosamine pathway leads to phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 and impairs the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin insulin biosynthetic pathway in RIN pancreatic beta-cells. Endocrinology 2004, 145(6):2845-2857.
37. Tanaka Y., Gleason C.E., Tran P.O., Harmon J.S., Robertson R.P. Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc Natl Acad Sci USA 1999, 96(19):10857-10862.
38. Robertson R.P., Harmon J., Tran P.O., Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004, 53(Suppl 1):S119-S124.
39. Tang C., Han P., Oprescu A.I., Lee S.C., Gyulkhandanyan A.V., Chan G.N., et al. Evidence for a role of superoxide generation in glucose-induced beta-cell dysfunction in vivo. Diabetes 2007, 56(11):2722-2731.
40. Tanaka Y., Tran P.O., Harmon J., Robertson R.P. A role for glutathione peroxidase in protecting pancreatic beta cells against oxidative stress in a model of glucose toxicity. Proc Natl Acad Sci USA 2002, 99(19):12363-12368.
41. Bregenholt S., Moldrup A., Blume N., Karlsen A.E., Nissen F.B., Tornhave D., et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 2005, 330(2):577-584.
42. Maeda H., Rajesh K.G., Maeda H., Suzuki R., Sasaguri S. Epidermal growth factor and insulin inhibit cell death in pancreatic beta cells by activation of PI3-kinase/AKT signaling pathway under oxidative stress. Transplant Proc 2004, 36(4):1163-1165.
43. Oliveira H.R., Verlengia R., Carvalho C.R., Britto L.R., Curi R., Carpinelli A.R. Pancreatic beta-cells express phagocyte-like NAD(P)H oxidase. Diabetes 2003, 52(6):1457-1463.
44. Tsubouchi H., Inoguchi T., Inuo M., Kakimoto M., Sonta T., Sonoda N., et al. Sulfonylurea as well as elevated glucose levels stimulate reactive oxygen species production in the pancreatic beta-cell line, MIN6-a role of NAD(P)H oxidase in beta-cells. Biochem Biophys Res Commun 2005, 326(1):60-65.
45. Inoguchi T., Nawata H. NAD(P)H oxidase activation: a potential target mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome. Curr Drug Targets 2005, 6(4):495-501.
46. Morgan D., Oliveira-Emilio H.R., Keane D., Hirata A.E., Santos da R.M., Bordin S., et al. Glucose, palmitate and pro-inflammatory cytokines modulate production and activity of a phagocyte-like NADPH oxidase in rat pancreatic islets and a clonal beta cell line. Diabetologia 2007, 50(2):359-369.
47. Newsholme P., Haber E.P., Hirabara S.M., Rebelato E.L., Procopio J., Morgan D., et al. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol 2007, 583(Pt 1):9-24.
48. Nakayama M., Inoguchi T., Sonta T., Maeda Y., Sasaki S., Sawada F., et al. Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an AT1 receptor antagonist. Biochem Biophys Res Commun 2005, 332(4):927-933.
49. Scheen A.J. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004, 64(22):2537-2565.
50. Lanone S., Bloc S., Foresti R., Almolki A., Taille C., Callebert J., et al. Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J 2005, 19(13):1890-1892.
51. Matsumoto H., Ishikawa K., Itabe H., Maruyama Y. Carbon monoxide and bilirubin from heme oxygenase-1 suppresses reactive oxygen species generation and plasminogen activator inhibitor-1 induction. Mol Cell Biochem 2006, 291(1-2):21-28.
52. Jiang F., Roberts S.J., Datla S., Dusting G.J. NO modulates NADPH oxidase function via heme oxygenase-1 in human endothelial cells. Hypertension 2006, 48(5):950-957.
53. Datla S.R., Dusting G.J., Mori T.A., Taylor C.J., Croft K.D., Jiang F. Induction of heme oxygenase-1 in vivo suppresses NADPH oxidase derived oxidative stress. Hypertension 2007, 50(4):636-642.
54. McCarty M.F. ''Iatrogenic Gilbert syndrome'' - a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses 2007, 69(5):974-994.
55. McCarty M.F. Clinical potential of Spirulina as a source of phycocyanobilin. J Med Food 2007, 10(4):566-570.
56. Terry M.J., Maines M.D., Lagarias J.C. Inactivation of phytochrome- and phycobiliprotein-chromophore precursors by rat liver biliverdin reductase. J Biol Chem 1993, 268(35):26099-26106.
57. Romay C., Gonzalez R., Ledon N., Remirez D., Rimbau V. C-phycocyanin: a biliprotein with antioxidant, anti-inflammatory and neuroprotective effects. Curr Protein Pept Sci 2003, 4(3):207-216.
58. Talior I., Yarkoni M., Bashan N., Eldar-Finkelman H. Increased glucose uptake promotes oxidative stress and PKC-delta activation in adipocytes of obese, insulin-resistant mice. Am J Physiol Endocrinol Metab 2003, 285(2):E295-E302.
59. Talior I., Tennenbaum T., Kuroki T., Eldar-Finkelman H. PKC-delta-dependent activation of oxidative stress in adipocytes of obese and insulin-resistant mice. role for NADPH oxidase. Am J Physiol Endocrinol Metab 2005, 288(2):E405-E411.
60. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114(12):1752-1761.
61. Boden G. Free fatty acids-the link between obesity and insulin resistance. Endocr Pract 2001, 7(1):44-51.
62. Wang X., Zhou J., Doyle M.E., Egan J.M. Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology 2001, 142(5):1820-1827.
63. Schulze M.B., Liu S., Rimm E.B., Manson J.E., Willett W.C., Hu F.B. Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle-aged women. Am J Clin Nutr 2004, 80(2):348-356.
64. Hodge A.M., English D.R., O'Dea K., Giles G.G. Glycemic index and dietary fiber and the risk of type 2 diabetes. Diabetes Care 2004, 27(11):2701-2706.
65. Barclay A.W., Petocz P., Millan-Price J., Flood V.M., Prvan T., Mitchell P., et al. Glycemic index, glycemic load, and chronic disease risk - a meta-analysis of observational studies. Am J Clin Nutr 2008, 87(3):627-637.
66. Chiasson J.L. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract 2006, 12(Suppl 1):25-30.
67. Pan C.Y. Reducing the risk of type 2 diabetes: early identification of high-risk individuals and treatment with acarbose. Curr Diabetes Rev 2007, 3(2):141-148.
68. van Dam R.M., Hu F.B. Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA 2005, 294(1):97-104.
69. Johnston K.L., Clifford M.N., Morgan L.M. Coffee acutely modifies gastrointestinal hormone secretion and glucose tolerance in humans: glycemic effects of chlorogenic acid and caffeine. Am J Clin Nutr 2003, 78(4):728-733.
70. McCarty M.F. A chlorogenic acid-induced increase in GLP-1 production may mediate the impact of heavy coffee consumption on diabetes risk. Med Hypotheses 2005, 64(4):848-853.
71. Green B.D., Flatt P.R. Incretin hormone mimetics and analogues in diabetes therapeutics. Best Pract Res Clin Endocrinol Metab 2007, 21(4):497-516.
72. Borboni P., Magnaterra R., Rabini R.A., Staffolani R., Porzio O., Sesti G., et al. Effect of biotin on glucokinase activity, mRNA expression and insulin release in cultured beta-cells. Acta Diabetol 1996, 33(2):154-158.
73. Yoshikawa H., Tajiri Y., Sako Y., Hashimoto T., Umeda F., Nawata H. Effects of biotin on glucotoxicity or lipotoxicity in rat pancreatic islets. Metabolism 2002, 51(2):163-168.
74. Zhang H., Osada K., Sone H., Furukawa Y. Biotin administration improves the impaired glucose tolerance of streptozotocin-induced diabetic Wistar rats. J Nutr Sci Vitaminol (Tokyo) 1997, 43(3):271-280.
75. Spence J.T., Koudelka A.P. Effects of biotin upon the intracellular level of cGMP and the activity of glucokinase in cultured rat hepatocytes. J Biol Chem 1984, 259(10):6393-6396.
76. Chauhan J., Dakshinamurti K. Transcriptional regulation of the glucokinase gene by biotin in starved rats. J Biol Chem 1991, 266(16):10035-10038.
77. McCarty M.F. CGMP may have trophic effects on beta cell function comparable to those of cAMP, implying a role for high-dose biotin in prevention/treatment of diabetes. Med Hypotheses 2006, 66(2):323-328.
78. McCarty M.F. High-dose biotin, an inducer of glucokinase expression, may synergize with chromium picolinate to enable a definitive nutritional therapy for type II diabetes. Med Hypotheses 1999, 52(5):401-406.
79. Baez-Saldana A., Zendejas-Ruiz I., Revilla-Monsalve C., Islas-Andrade S., Cardenas A., Rojas-Ochoa A., et al. Effects of biotin on pyruvate carboxylase, acetyl-CoA carboxylase, propionyl-CoA carboxylase, and markers for glucose and lipid homeostasis in type 2 diabetic patients and nondiabetic subjects. Am J Clin Nutr 2004, 79(2):238-243.
80. Fernandez-Mejia C. Pharmacological effects of biotin. J Nutr Biochem 2005, 16(7):424-427.
81. McCarty M.F. Exenatide and biotin in conjunction with a protein-sparing fast for normalization of beta cell function in type 2 diabetics. Med Hypotheses 2007, 69(4):928-932.
82. Barnard R.J., Massey M.R., Cherny S., O'Brien L.T., Pritikin N. Long-term use of a high-complex-carbohydrate, high-fiber, low-fat diet and exercise in the treatment of NIDDM patients. Diabetes Care 1983, 6(3):268-273.
83. Barnard R.J., Jung T., Inkeles S.B. Diet and exercise in the treatment of NIDDM. The need for early emphasis. Diabetes Care 1994, 17(12):1469-1472.